News | Infectious diseases

News

Around 5,000 courses of molnupiravir dispensed in England in first month of use

A further 5,000 vials of the monoclonal antibody sotrovimab have been dispensed for the treatment of COVID-19, up to 16 January 2022.…

Published: 25 January 2022

Feature

Everything you need to know about the COVID-19 therapy trials

There are thousands of clinical trials investigating treatments and preventative measures for COVID-19.…

Published: 20 January 2022

News

World Health Organization recommends JAK inhibitor for treatment of severe or critical COVID-19

The monoclonal antibody sotrovimab has also been conditionally recommended for treating mild or moderate COVID-19 in patients who are at high risk of hospitalisation.…

Published: 17 January 2022

News

High-risk COVID-19 patients may need to seek out own referral for community-based treatment after ‘data mismatch’

Patients eligible for COVID-19 medicines delivery unit treatment are advised to contact their GP or NHS 111 for a referral if they have not been contacted within 24 hours of their positive test result.…

Published: 7 January 2022

News

Pfizer COVID-19 antiviral paxlovid authorised by MHRA

Paxlovid is the second oral antiviral to be approved for the treatment of mild-to-moderate COVID-19 in high-risk adults, after molnupiravir.…

Published: 4 January 2022

Opinion

Hear it here first: a year of the PJ Pod

During our first full year of The PJ Pod, we explored a range of topics including mental health in the face of COVID-19, hidden disabilities in pharmacy and a closer look at the diversity of the MPharm degree.…

Published: 30 December 2021

News

Government advisers recommend COVID-19 vaccines for clinically vulnerable children aged 5 to 11 years

The Joint Committee on Vaccination and Immunisation has advised that children aged 5 to 11 years who are in a clinical risk group, or who are household contacts of anyone who is immunosuppressed, should be offered the vaccine.…

Published: 22 December 2021

News

Government orders 4.3 million further doses of COVID-19 antivirals

The 1.8 million doses of molnupiravir and 2.5 million doses of PF-07321332/ritonavir are in addition to the courses that were announced in October 2021.…

Published: 22 December 2021

News